Search Results

Abbott (NYSE: ABT) will announce its second-quarter 2024 financial results on Thursday, July 18, before the market opens.

Abbott (NYSE: ABT) today announced U.S. Food and Drug Administration (FDA) clearance for two new over-the-counter continuous glucose monitoring (CGM) systems – Lingo™ and Libre Rio™, which are based on Abbott’s world-leading FreeStyle Libre® continuous glucose monitoring technology1, now used by about 6 million people globally2.

Great Point Partners, a Greenwich-based investment firm focused exclusively on the health care industry, announced the acquisition of Lyocontract GmbH, a premium independent drug product contract development and manufacturing organization based in Ilsenburg, Germany.

Abbott will announce its first-quarter 2024 financial results on Wednesday, April 17, before the market opens.

Abbott (NYSE: ABT) today announced financial results for the first quarter ended March 31, 2024.